modelProguanil
Extends from Pharmacolibrary.Drugs.ATC.P.P01BB01.
Information
| name: | Proguanil | |
| ATC code: | P01BB01 | route: | oral |
| compartments: | 1 | |
| dosage: | 200 | mg |
| volume of distribution: | 342 | L |
| clearance: | 23 | L/h |
| other parameters in model implementation | ||
Proguanil is an antimalarial drug, primarily used for the prevention and treatment of malaria, often in combination with atovaquone. It acts by inhibiting dihydrofolate reductase in the malaria parasite. Proguanil is still approved and in clinical use for malaria prophylaxis.
Pharmacokinetics
Pharmacokinetic parameters reported in healthy adult volunteers following a single oral dose of proguanil.
References
Hussein, Z, et al., & Canfield, CJ (1996). Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone. British journal of clinical pharmacology 42(5) 589–597. DOI:10.1111/j.1365-2125.1996.tb00114.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/8951190
Helsby, NA, et al., & Breckenridge, AM (1990). The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. British journal of clinical pharmacology 30(4) 593–598. DOI:10.1111/j.1365-2125.1990.tb03818.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/2291871
McGready, R, et al., & Nosten, F (2003). The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. European journal of clinical pharmacology 59(7) 545–552. DOI:10.1007/s00228-003-0652-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12955371
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)